A Closer Look At AMGN and REGN Earnings Report
The biotech big-cap stocks have been taking a beating since the beginning of the year. There are many names out there, but we are taking a closer look at these two big pharmaceuticals companies after their first-quarter earnings report.
- Amgen Inc (AMGN:NASDAQ)
For Amgen Inc (AMGN), the leading sales products in sales are Neulasta and Embrel with both over $1 billion in sales. A closer look at the company revenue shown the growth has been plateau for the last four quarters. In Q1 2018, revenue was $5.60 billion compared to $5.50 billion in Q1 2017, but from the year 2017, Q2-Q4 show no growth in revenue. In effect, the stock performance continues to decline, for Year-to-Date it is down -3.11% and for 3 months down -4.67%.
From our website, here is a complete earnings recap https://www.tradersfish.com/Earning/amgen-inc
2. Regeneron Pharmaceuticals Inc (REGN:NASDAQ)
Regeneron Pharmaceuticals Inc (REGN) has five products in sales, with EYLEA global sales $1.60 billion in Q1 2018, while the rest of their product sales is gloomy. As a result, stock performance for the Year-To-dATE -24.19%, and 3 months down -15.87%.
Here is the earnings recap for the last 5 quarters. https://www.tradersfish.com/Earning/regeneron-pharmaceuticals-inc
Amgen Inc (AMGN) has Repatha (evolocumab) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD). While Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (SNY) has Praluent (alirocumab) for the similar treatment. Conversely, the two company on a different path for sales growth.
A comparison between Amgen and Regeneron sales
In summary, these two companies latest earnings report doesn't show much excitement for investment, but we are optimistic that it will turnaround in future.
Disclosure: I (we) do not hold any positions with the above-mentioned stocks. This is opinion and ideas only. Always do your own due diligence and seek for financial advisers.